JP5775246B2 - 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法 - Google Patents
関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法 Download PDFInfo
- Publication number
- JP5775246B2 JP5775246B2 JP2007548653A JP2007548653A JP5775246B2 JP 5775246 B2 JP5775246 B2 JP 5775246B2 JP 2007548653 A JP2007548653 A JP 2007548653A JP 2007548653 A JP2007548653 A JP 2007548653A JP 5775246 B2 JP5775246 B2 JP 5775246B2
- Authority
- JP
- Japan
- Prior art keywords
- pain
- treatment
- drug
- joint
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 title claims description 69
- 239000003814 drug Substances 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 30
- 208000006820 Arthralgia Diseases 0.000 title claims description 18
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims description 56
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims description 56
- 229940073454 resiniferatoxin Drugs 0.000 claims description 56
- 238000011282 treatment Methods 0.000 claims description 55
- 239000007924 injection Substances 0.000 claims description 52
- 238000002347 injection Methods 0.000 claims description 52
- 208000002193 Pain Diseases 0.000 claims description 43
- 230000036407 pain Effects 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 30
- 210000000281 joint capsule Anatomy 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 210000000988 bone and bone Anatomy 0.000 claims description 18
- 239000003589 local anesthetic agent Substances 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 12
- 210000005036 nerve Anatomy 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 208000004371 toothache Diseases 0.000 claims description 10
- 206010006002 Bone pain Diseases 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 206010034464 Periarthritis Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 6
- 230000005499 meniscus Effects 0.000 claims description 6
- 208000008035 Back Pain Diseases 0.000 claims description 5
- 206010007710 Cartilage injury Diseases 0.000 claims description 5
- 206010061223 Ligament injury Diseases 0.000 claims description 5
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 238000002674 endoscopic surgery Methods 0.000 claims description 5
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 208000013465 muscle pain Diseases 0.000 claims description 5
- 230000017074 necrotic cell death Effects 0.000 claims description 5
- 208000028169 periodontal disease Diseases 0.000 claims description 5
- 230000003239 periodontal effect Effects 0.000 claims description 5
- 210000003281 pleural cavity Anatomy 0.000 claims description 5
- 201000004595 synovitis Diseases 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 206010053692 Wound complication Diseases 0.000 claims description 4
- 230000002638 denervation Effects 0.000 claims description 4
- 208000002925 dental caries Diseases 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000007443 liposuction Methods 0.000 claims description 4
- 210000004126 nerve fiber Anatomy 0.000 claims description 4
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 206010023230 Joint stiffness Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 239000004053 dental implant Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000000944 nerve tissue Anatomy 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 230000003040 nociceptive effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000001223 septic arthritis Diseases 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 208000002847 Surgical Wound Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 210000003741 urothelium Anatomy 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 2
- 229910001424 calcium ion Inorganic materials 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010069364 Meniscal degeneration Diseases 0.000 claims 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000002604 ultrasonography Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 229960002504 capsaicin Drugs 0.000 description 8
- 235000017663 capsaicin Nutrition 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 6
- 229960005015 local anesthetics Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002887 neurotoxic effect Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 206010002153 Anal fissure Diseases 0.000 description 3
- 208000016583 Anus disease Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000009531 Fissure in Ano Diseases 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 208000002472 Morton Neuroma Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 208000009905 Neurofibromatoses Diseases 0.000 description 3
- 208000004983 Phantom Limb Diseases 0.000 description 3
- 206010056238 Phantom pain Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- -1 iophenylate Chemical compound 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 210000000323 shoulder joint Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001148 spastic effect Effects 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010061159 Foot deformity Diseases 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 208000001963 Hallux Valgus Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010072970 Meniscus injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 201000009859 Osteochondrosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 229960004647 iopamidol Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 108010012215 Ornipressin Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940050457 ciprofloxacin 750 mg Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940005649 gadopentetate Drugs 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- FUTMROFFABQWML-UHFFFAOYSA-N nonanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCC(O)=O.CCCCCCCCC(O)=O FUTMROFFABQWML-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- MUNMIGOEDGHVLE-LGYYRGKSSA-N ornipressin Chemical compound NC(=O)CNC(=O)[C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 MUNMIGOEDGHVLE-LGYYRGKSSA-N 0.000 description 1
- 229960004571 ornipressin Drugs 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008349 purified phosphatidyl choline Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940083604 sodium iothalamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 239000000105 vanilloid receptor agonist Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CH2004/000756 WO2006069451A1 (de) | 2004-12-28 | 2004-12-28 | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525504A JP2008525504A (ja) | 2008-07-17 |
| JP2008525504A5 JP2008525504A5 (enExample) | 2015-01-15 |
| JP5775246B2 true JP5775246B2 (ja) | 2015-09-09 |
Family
ID=34959549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548653A Expired - Lifetime JP5775246B2 (ja) | 2004-12-28 | 2004-12-28 | 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080139641A1 (enExample) |
| EP (1) | EP1838301B1 (enExample) |
| JP (1) | JP5775246B2 (enExample) |
| CA (1) | CA2594202C (enExample) |
| DK (1) | DK1838301T3 (enExample) |
| ES (1) | ES2533256T3 (enExample) |
| PL (1) | PL1838301T3 (enExample) |
| WO (1) | WO2006069451A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020132553A1 (en) * | 2018-12-21 | 2020-06-25 | Sorrento Therapeutics, Inc. | Perineural administration of resiniferatoxin for treatment of maladaptive pain |
| US12029725B2 (en) | 2019-01-22 | 2024-07-09 | Vivasor, Inc. | Method for treating osteoarthritis pain by administering resiniferatoxin |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100076037A1 (en) | 2006-11-02 | 2010-03-25 | Chiang Lillian W | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma |
| WO2010011597A2 (en) * | 2008-07-22 | 2010-01-28 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| EP3269371A1 (en) | 2011-06-10 | 2018-01-17 | Queen Mary University of London | Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease |
| EP2879660A1 (de) * | 2012-08-03 | 2015-06-10 | Mestex AG | Resiniferatoxin-lösung |
| JP6144775B2 (ja) | 2012-12-12 | 2017-06-07 | クイーン マリー アンド ウエストフィールド カレッジ， ユニバーシティー オブ ロンドン | 腎臓病の治療に使用されるアーテミシニンおよびその誘導体 |
| US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
| JP7100635B2 (ja) | 2016-11-02 | 2022-07-13 | セントレクシオン セラピューティクス コーポレイション | 安定な水性カプサイシン注射製剤およびその医学的使用 |
| EP3641746B1 (en) * | 2017-06-19 | 2024-11-20 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| IL272036B2 (en) | 2017-07-20 | 2025-01-01 | Centrexion Therapeutics Corp | Methods and compositions for treating pain using capsaicin |
| KR20200051771A (ko) * | 2017-09-11 | 2020-05-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | 레시니페라톡신 제형 |
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| CN110123833A (zh) * | 2019-05-31 | 2019-08-16 | 龚啸元 | 一种关节镜手术用灌流液及其制备方法 |
| EP4487872A3 (en) * | 2020-04-15 | 2025-03-26 | Grünenthal GmbH | Resiniferatoxin compositions |
| WO2025153517A1 (en) | 2024-01-15 | 2025-07-24 | Grünenthal GmbH | Treating knee joint pain by injecting resiniferatoxin at ultra low doses |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3104085A (en) | 1960-07-18 | 1963-09-17 | Ind Paper Log Inc | Compressed fibrous articles |
| US4939149A (en) * | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
| US4997853A (en) * | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
| AU5744490A (en) * | 1989-05-15 | 1990-12-18 | Afferon Corporation | Composition and method for neural desensitization |
| ATE219674T1 (de) | 1997-03-13 | 2002-07-15 | James N Campbell | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
| GB9711962D0 (en) | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| US6780650B2 (en) * | 2000-10-16 | 2004-08-24 | Ortho-Mcneil Pharmaceutical, Inc. | Ligand binding assays for vanilloid receptors |
| US20040047807A1 (en) * | 2001-01-24 | 2004-03-11 | Dominik Meyer | Use of neurotoxic substances in producing a medicament for treating joint pains |
| WO2002076444A1 (en) | 2001-03-22 | 2002-10-03 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Molecular neurochirurgerie for pain control administering locally capsaicin or resiniferatoxin |
| US20030104085A1 (en) * | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| JP2006513267A (ja) * | 2002-12-18 | 2006-04-20 | アルゴルクス ファーマスーティカルズ，インク | カプサイシノイドの投与 |
| ES2355109T3 (es) * | 2004-12-22 | 2011-03-22 | Mestex Ag | Mezcla de un agonista de receptor de vainilloide con una sustancia inhibidora de la regeneración nerviosa, su utilización para la fabricación de un analgésico y procedimiento de aplicación de este fármaco. |
-
2004
- 2004-12-28 PL PL04802396T patent/PL1838301T3/pl unknown
- 2004-12-28 ES ES04802396.4T patent/ES2533256T3/es not_active Expired - Lifetime
- 2004-12-28 US US11/722,779 patent/US20080139641A1/en not_active Abandoned
- 2004-12-28 WO PCT/CH2004/000756 patent/WO2006069451A1/de not_active Ceased
- 2004-12-28 DK DK04802396.4T patent/DK1838301T3/en active
- 2004-12-28 EP EP04802396.4A patent/EP1838301B1/de not_active Expired - Lifetime
- 2004-12-28 JP JP2007548653A patent/JP5775246B2/ja not_active Expired - Lifetime
- 2004-12-28 CA CA 2594202 patent/CA2594202C/en not_active Expired - Lifetime
-
2010
- 2010-04-07 US US12/755,994 patent/US9044452B2/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020132553A1 (en) * | 2018-12-21 | 2020-06-25 | Sorrento Therapeutics, Inc. | Perineural administration of resiniferatoxin for treatment of maladaptive pain |
| JP2022514014A (ja) * | 2018-12-21 | 2022-02-09 | ソレント・セラピューティクス・インコーポレイテッド | 不適応性疼痛の処置のためのレシニフェラトキシンの神経周囲投与 |
| US12144886B2 (en) | 2018-12-21 | 2024-11-19 | Vivasor, Inc. | Perineural administration of resiniferatoxin for treatment of maladaptive pain |
| US12029725B2 (en) | 2019-01-22 | 2024-07-09 | Vivasor, Inc. | Method for treating osteoarthritis pain by administering resiniferatoxin |
Also Published As
| Publication number | Publication date |
|---|---|
| US9044452B2 (en) | 2015-06-02 |
| PL1838301T3 (pl) | 2015-08-31 |
| DK1838301T3 (en) | 2015-04-27 |
| ES2533256T3 (es) | 2015-04-08 |
| CA2594202C (en) | 2013-12-03 |
| EP1838301A1 (de) | 2007-10-03 |
| US20100196281A1 (en) | 2010-08-05 |
| JP2008525504A (ja) | 2008-07-17 |
| EP1838301B1 (de) | 2015-01-28 |
| US20080139641A1 (en) | 2008-06-12 |
| CA2594202A1 (en) | 2006-07-06 |
| WO2006069451A1 (de) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775246B2 (ja) | 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法 | |
| CA2592086C (en) | Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller | |
| Murray et al. | Lower limb blocks | |
| Klamt et al. | Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia | |
| JP5080983B2 (ja) | バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法 | |
| JP2008525504A5 (enExample) | ||
| JP2004521112A (ja) | 関節痛治療薬を製造することへの神経毒性物質の使用 | |
| JP2008533140A (ja) | 術後鎮痛剤の低減 | |
| Kulkarni et al. | Randomized prospective comparative study of adductor canal block vs periarticular infiltration on early functional outcome after unilateral total knee arthroplasty | |
| JP2005538983A (ja) | 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法 | |
| EP3045179B1 (en) | Local anesthesia pain-relieving time-delay agent | |
| RU2354383C2 (ru) | Способ лечения перонеального синдрома | |
| CN100581544C (zh) | 用于勃起机能障碍治疗和逆转的可注射药物组合物 | |
| RU2352339C2 (ru) | Способ лечения артралгии | |
| RU2235521C2 (ru) | Способ лечения каузалгии после ампутации нижних конечностей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120402 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120409 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120427 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120604 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120718 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141024 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141030 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20141117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150512 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150703 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5775246 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |